DNDavid Nadal

David Nadal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David Nadal has a total of 93 co-authors. Here are the top co-authors by number of shared publications:

  • Christoph Berger

    Laboratory for Experimental Infectious Diseases and Cancer Research of the Division of Infectious Diseases, University Children's Hospital of Zurich, 8032 Zurich, Switzerland

    8 shared publications
  • Martin Altwegg

    Division of Infectious Diseases,1 Division of Oncology, University Children's Hospital of Zurich, Zurich,2 Division of Oncology, University Children's Hospital of Bern,3 Institute of Infectious Diseases, University of Bern, Bern,4 Bio-Analytica AG, Lucerne, Switzerland5

    6 shared publications
  • Franziska Zucol

    Laboratory for Experimental Infectious Diseases and Cancer Research of the Division of Infectious Diseases, University Children's Hospital of Zurich, 8032 Zurich, Switzerland

    4 shared publications
  • Michele Bernasconi

    Department of Pediatric Hematology and Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland; Translational Cancer Research, Department for BioMedical Research (DBMR), University of Bern, 3008 Bern, Switzerland

    4 shared publications
  • Oliver Greiner

    Division of Infectious Diseases,1 Division of Oncology, University Children's Hospital of Zurich, CH-8032 Zurich,2 Institute of Medical Microbiology, University of Berne, CH-3010 Berne, Switzerland3

    4 shared publications
  • Philip J. R. Day

    Division of Infectious Diseases,1 Division of Oncology, University Children's Hospital of Zurich, CH-8032 Zurich,2 Institute of Medical Microbiology, University of Berne, CH-3010 Berne, Switzerland3

    4 shared publications

Latest Publications

  • Immune activation suppresses initiation of lytic Epstein-Barr virus infection

    by Kristin Ladell, Marcus Dorner, Ludwig Zauner, Christoph Berger, Franziska Zucol, Michele Bernasconi, Felix K. Niggli, Roberto F. Speck, David Nadal

    Primary infection with Epstein-Barr virus (EBV) is asymptomatic in children with immature immune systems but may manifest as infectious mononucleosis, a vigorous immune activation, in adolescents or adults with mature immune systems. Infectious mononucleosis and chronic immune activation are linked to increased risk for EBV-associated lymphoma. Here we show that EBV initiates progressive lytic infection by expression of BZLF-1 and the late lytic genes gp85 and gp350/220 in cord blood mononuclear cells (CBMC) but not in peripheral blood mononuclear cells (PBMC) from EBV-naive adults after EBV infection ex vivo. Lower levels of proinflammatory cytokines in CBMC, used to model a state of minimal immune activation and immature immunity, than in PBMC were associated with lytic EBV infection. Triggering the innate immunity specifically via Toll-like receptor-9 of B cells substantially suppressed BZLF-1 mRNA expression in acute EBV infection ex vivo and in anti-IgG-stimulated chronically latently EBV-infected Akata Burkitt lymphoma cells. This was mediated in part by IL-12 and IFN-gamma. These results identify immune activation as critical factor for the suppression of initiation of lytic EBV infection. We hypothesize that immune activation contributes to EBV-associated lymphomagenesis by suppressing lytic EBV and in turn promotes latent EBV with transformation potential.


  • Distribution patterns of β‐ and γ‐herpesviruses within Waldeyer's ring organs

    by Christoph Berger, Martina Hug, Claudine Gysin, Luciano Molinari, Martina Frei, Walter Bossart, David Nadal

    The Waldeyer's ring designates a functional unit of lymphoid tissue within the pharynx including the adenoids and tonsils. To gain insight into distribution patterns of β- and γ-human herpesviruses (HHVs) and their potential mutual influences at their natural portal of entry, quantitative polymerase chain reaction (qPCR) assays were applied to adenoids and tonsils obtained from 30 children. DNA of Epstein-Barr virus (EBV), cytomegalovirus (CMV), HHV-6, HHV-7, and HHV-8 was detected in adenoids, tonsils, or both of 24 (80%), 19 (63%), 23 (77%), 23 (77%), and 0 (0%) children, respectively. EBV, CMV, HHV-6, and -7 localized in both adenoids and tonsils from 92%, 37%, 52%, and 70% of children, respectively, with the virus detectable by qPCR. The amount of EBV was 2–10-fold higher than of other HHVs and correlated in autologous organs (P = 0.01) as did the amount of HHV-7 (P = 0.002). The amount of CMV correlated with the HHV-6 amount in adenoids (P = 0.028) and tonsils (P = 0.007), and with the amount of HHV-7 in adenoids (P < 0.01). Levels of HHV-6 DNA were lower in adenoids with detectable CMV DNA than in adenoids without detectable CMV DNA (P = 0.0062). Inversely, CMV and HHV-7 levels were higher in adenoids with than in adenoids without detectable EBV DNA (P = 0.019 and P = 0.039, respectively).Thus, β- and γ-HHV exhibit distinct distribution behaviors in Waldeyer's ring organs and seem to interact. This may be of medical importance in immunocompromised hosts who are likely to reactivate HHVs causing severe morbidity and death. J. Med. Virol. 79: 1147–1152, 2007.


    • 5 May 2007
      • Vol. 137, 239-51

    Swiss recommendations for the management of varicella zoster virus infections.

    by W Kempf, P Meylan, S Gerber, C Aebi, R Agosti, S Büchner, B Coradi, J Garweg, Hh Hirsch, C Kind, et al.

    Infections with varicella zoster virus (VZV) are common viral infections associated with significant morbidity. Diagnosis and management are complex, particularly in immunocompromised patients and during pregnancy. The present recommendations have been established by a multidisciplinary panel of specialists and endorsed by numerous Swiss medical societies involved in the medical care of such patients (Appendix). The aim was to improve the care of affected patients and to reduce complications.


  • Open Access

    Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein–Barr virus in Burkitt's lymphoma Akata cells

    by Markus P. Rechsteiner, Christoph Berger, Matthias Weber, Jürg A. Sigrist, David Nadal, Michele Bernasconi

    Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) blocks B-cell receptor (BCR) signalling after BCR cross-linking to inhibit activation of lytic EBV, and ectopically expressed LMP2B negatively regulates LMP2A. Here, it is demonstrated that silencing of LMP2B in EBV-harbouring Burkitt's lymphoma Akata cells results in reduced expression of EBV immediate-early lytic BZLF1 gene mRNA and late lytic gp350/220 protein upon BCR cross-linking. Similarly, reduction of lytic EBV activation was observed in Akata cells overexpressing LMP2A. In contrast, silencing of LMP2A expression resulted in higher lytic EBV mRNA and protein expression in BCR cross-linked Akata cells. These observations indicate a role for LMP2B distinct from that of LMP2A in regulation of lytic EBV activation in the host cell and support the hypothesis that LMP2B exhibits a negative-regulatory effect on the ability of LMP2A to maintain EBV latency by preventing the switch to lytic replication.


  • Open Access

    Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells

    by Sieta P Rao, Markus P Rechsteiner, Christoph Berger, Jürg A Sigrist, David Nadal, Michele Bernasconi

    Epigenetic silencing of regulatory genes by aberrant methylation contributes to tumorigenesis. DNA methyltransferase inhibitors (DNMTI) represent promising new drugs for anti-cancer therapies. The DNMTI 5-Azacytidine is effective against myelodysplastic syndrome, but induces switching of latent to lytic Epstein-Barr virus (EBV) in vitro and results in EBV DNA demethylation with the potential of induction of lytic EBV in vivo. This is of considerable concern given that recurrent lytic EBV has been linked with an increased incidence of EBV-associated lymphomas. Based on the distinct properties of action we hypothesized that the newer DNMTI Zebularine might differ from 5-Azacytidine in its potential to induce switching from latent to lytic EBV. Here we show that both 5-Azacytidine and Zebularine are able to induce expression of E-cadherin, a cellular gene frequently silenced by hypermethylation in cancers, and thus demonstrate that both DNMTI are active in our experimental setting consisting of EBV-harboring Burkitt's lymphoma Akata cells. Quantification of mRNA expression of EBV genes revealed that 5-Azacytidine induces switching from latent to lytic EBV and, in addition, that the immediate-early lytic infection progresses to early and late lytic infection. Furthermore, 5-Azacytidine induced upregulation of the latent EBV genes LMP2A, LMP2B, and EBNA2 in a similar fashion as observed following switching of latent to lytic EBV upon cross-linking of the B-cell receptor. In striking contrast, Zebularine did not exhibit any effect neither on lytic nor on latent EBV gene expression. Thus, Zebularine might be safer than 5-Azacytidine for the treatment of cancers in EBV carriers and could also be applied against EBV-harboring tumors, since it does not induce switching from latent to lytic EBV which may result in secondary EBV-associated malignancies.


  • Real-Time Quantitative Broad-Range PCR Assay for Detection of the 16S rRNA Gene Followed by Sequencing for Species Identification

    by Franziska Zucol, Roland A. Ammann, Christoph Berger, Christoph Aebi, Martin Altwegg, Felix K. Niggli, David Nadal

    Here we determined the analytical sensitivities of broad-range real-time PCR-based assays employing one of three different genomic DNA extraction protocols in combination with one of three different primer pairs targeting the 16S rRNA gene to detect a panel of 22 bacterial species. DNA extraction protocol III, using lysozyme, lysostaphin, and proteinase K, followed by PCR with the primer pair Bak11W/Bak2, giving amplicons of 796 bp in length, showed the best overall sensitivity, detecting DNA of 82% of the strains investigated at concentrations of ≤10 2 CFU in water per reaction. DNA extraction protocols I and II, using less enzyme treatment, combined with other primer pairs giving shorter amplicons of 466 bp and 342 or 346 bp, respectively, were slightly more sensitive for the detection of gram-negative but less sensitive for the detection of gram-positive bacteria. The obstacle of detecting background DNA in blood samples spiked with bacteria was circumvented by introducing a broad-range hybridization probe, and this preserved the minimal detection limits observed in samples devoid of blood. Finally, sequencing of the amplicons generated using the primer pair Bak11W/Bak2 allowed species identification of the detected bacterial DNA. Thus, broad-spectrum PCR targeting the 16S rRNA gene in the quantitative real-time format can achieve an analytical sensitivity of 1 to 10 CFU per reaction in water, avoid detection of background DNA with the introduction of a broad-range probe, and generate amplicons that allow species identification of the detected bacterial DNA by sequencing. These prerequisites are important for its application to blood-containing patient samples.


  • Open Access

    Quantitative profiling of housekeeping and Epstein-Barr virus gene transcription in Burkitt lymphoma cell lines using an oligonucleotide microarray

    by Michele Bernasconi, Christoph Berger, Jürg A Sigrist, Athos Bonanomi, Jens Sobek, Felix K Niggli, David Nadal

    Background: The Epstein-Barr virus (EBV) is associated with lymphoid malignancies, including Burkitt's lymphoma (BL), and can transform human B cells in vitro. EBV-harboring cell lines are widely used to investigate lymphocyte transformation and oncogenesis. Qualitative EBV gene expression has been extensively described, but knowledge of quantitative transcription is lacking. We hypothesized that transcription levels ofEBNA1, the gene essential for EBV persistence within an infected cell, are similar in BL cell lines.Results: To compare quantitative gene transcription in the BL cell lines Namalwa, Raji, Akata, Jijoye, and P3HR1, we developed an oligonucleotide microarray chip, including 17 housekeeping genes, six latent EBV genes (EBNA1,EBNA2,EBNA3A,EBNA3C,LMP1,LMP2), and four lytic EBV genes (BZLF1,BXLF2,BKRF2,BZLF2), and used the cell line B95.8 as a reference for EBV gene transcription. Quantitative polymerase chain reaction assays were used to validate microarray results. We found that transcription levels of housekeeping genes differed considerably among BL cell lines. Using a selection of housekeeping genes with similar quantitative transcription in the tested cell lines to normalize EBV gene transcription data, we showed that transcription levels ofEBNA1were quite similar in very different BL cell lines, in contrast to transcription levels of other EBV genes. As demonstrated with Akata cells, the chip allowed us to accurately measure EBV gene transcription changes triggered by treatment interventions.Conclusion: Our results suggest uniformEBNA1transcription levels in BL and that microarray profiling can reveal novel insights on quantitative EBV gene transcription and its impact on lymphocyte biology.


  • Open Access

    Disseminated Fusarium oxysporum Infection in Hemophagocytic Lymphohistiocytosis

    by M. Albisetti, R. P. Lauener, F. K. Niggli, D. Nadal, T. Güngör, G. Schär

    The portal of entry of disseminated Fusarium spp. infections is still not clearly defined. We report on a disseminated Fusarium oxysporum infection occurring during a long period of severe neutropenia in a child with hemophagocytic lymphohistiocytosis. A nasogastric feeding tube was the possible source of entry of the fungus.


  • Open Access

    G-CSF and IL-8 for early diagnosis of sepsis in neonates and critically ill children – safety and cost effectiveness of a new laboratory prediction model: study protocol of a randomized controlled trial [ISRCTN91123847]

    by Thomas Horisberger, Stephan Harbarth, David Nadal, Oskar Baenziger, Joachim E Fischer

    Introduction: Bacterial infection represents a serious risk in neonates and critically ill paediatric patients. Current clinical practice is characterized by frequent antibiotic treatment despite low incidence of true infection. However, some patients escape early diagnosis and progress to septic shock. Many new markers, including cytokines, have been suggested to improve decision making, but the clinical efficacy of these techniques remains uncertain. Therefore, we will test the clinical efficacy of a previously validated diagnostic strategy to reduce antibiotic usage and nosocomial infection related morbidity. Methods: All patients admitted to the multidisciplinary neonatal and paediatric intensive care unit of a university children's hospital will be included. Patients will be allocated either to routine sepsis work up or to the intervention strategy with additional cytokine measurements. Physicians will be requested to estimate the pre-test probability of sepsis and pneumonia at initial suspicion. In the treatment arm, physicians will receive raw cytokine results, the likelihood ratio and the updated post-test probability. A high post-test probability will suggest that immediate initiation of antibiotic treatment is appropriate, whereas a low post-test probability will be supportive of watchful waiting or discontinuing prophylactic empirical therapy. Physicians may overrule the suggestions resulting from the post-test probability. Conclusion: This trial will ascertain the clinical efficacy of introducing new diagnostic strategies consisting of pre-test probability estimate, novel laboratory markers, and computer-generated post-test probability in infectious disease work up in critically ill newborns and children.


  • Open Access

    Detection of Haemophilus influenzae Type b by Real-Time PCR

    by Adrian Marty, Oliver Greiner, Philip J. R. Day, Sibylle Gunziger, Kathrin MühLemann, David Nadal

    A real-time PCR assay targeting the capsulation locus of Haemophilus influenzae type b (Hib) was developed. The linear detection range was from 1 to 10 6 microorganisms per reaction mixture. No H. influenzae other than Hib or any other control bacteria typically found in the upper respiratory tract was detected.